Marie-Eve Beaulieu

Marie-Eve Beaulieu is a highly skilled and experienced biotechnology and pharmacology expert with a passion for protein biophysics. She pursued her Ph.D. in Pharmacology at the Université de Sherbrooke in Canada and obtained her undergraduate degree from Cegep de Sherbrooke. Following her academic pursuits, she completed post-doctoral fellowships at Theratechnologies Inc. and the Vall d'Hebron Institute of Oncology, where she discovered the cell-penetrating activity of Omomyc-derived molecules. Consequently, she co-founded Peptomyc, a biotech company that develops first-in-class MYC inhibitors to help cancer patients. With her flawless leadership skills, Beaulieu established the protein purification platform, executed various business development activities, and raised a total of 10 million euros in public and private funding to date. Her true passion lies in translating valuable clinical outcomes into success stories for patients, making her a visionary leader in the oncology space.